Boundless Bio (BOLD) Q3 2026 earnings summary

Executive summary

• Q3 net loss narrowed to $5.4M from $13.9M YoY as operating expenses fell with trial wind-downs and workforce reductions; no product revenue.

• Operations are being wound down ahead of a proposed Serapha merger; the combined business plans to focus on SERP-01 and discontinue legacy ecDTx development.

Financial highlights

• Q3 2026 operating expenses were $6.2M versus $15.1M YoY; operating loss was $6.2M versus $15.1M.

• Q3 R&D was $1.4M, down $9.2M YoY; G&A was $4.8M, up $0.3M, including $1.3M of merger transaction costs.

• Nine-month net loss was $42.6M versus $45.3M; operating expenses were $45.1M versus $49.6M, while other income fell to $2.4M from $4.2M.

• Q3 basic and diluted net loss per share was $0.23 versus $0.62; 9M loss per share was $1.89 versus $2.03.

Outlook and guidance

• Expected merger close is Q4 2026, subject to stockholder approvals, Nasdaq listing, at least $200M in Serapha financing proceeds, and other closing conditions.

• A pre-closing cash dividend is currently expected at $44M–$48M, subject to adjustment based on net cash at closing and the merger terms.

• Excluding the anticipated dividend and proposed merger, current liquidity is expected to fund operations through the anticipated closing and for at least 12 months from the report date.

• Following the merger, the combined business plans to advance SERP-01; if the merger fails, alternatives include ecDTx development, collaborations, financing, another transaction, or liquidation.